| abstract |
(57) [Summary] [Purpose] A novel taxol administration that administers taxol for a shorter period than the current infusion protocol of 6 to 24 hours and minimizes the harmful effects induced by administration of taxol. The purpose is to provide a form. Compositions formulated and packaged to be administered to a patient suffering from cancer for administration over a period of not more than 24 hours in divided, or sequential or simultaneous, anti-tumor effective. An anticancer agent comprising an amount of taxol and a drug sufficient to prevent a fatal anaphylactic-like reaction. |